论文部分内容阅读
目的评价莫西沙星对重症胰腺炎患者感染预防的有效性和安全性。方法采用随机、双盲、对照开放试验。临床确诊重症急性胰腺炎的患者随机分为实验组与对照组,实验组每日应用莫西沙星400mg,对照组每日应用环丙沙星400mg+甲硝唑1.25g,疗程均为7～14d,记录两组患者生命体征、APACHⅡ评分、血常规、肝肾功能以及恶心、呕吐、腹痛、腹胀等,统计患者感染发生率及死亡率。结果两组均有28例患者纳入本研究,各有26、25例可进行疗效评价,各组有24例可进行安全性评价。腹腔感染发生率实验组为14.3%,对照组为17.9%;不良反应发生率实验组为15.3%,对照组为20%。结论在急性胰腺炎预防性应用抗生素治疗中,单用莫西沙星可达到环丙沙星+甲硝唑联用同样的效果。
Objective To evaluate the efficacy and safety of moxifloxacin in the prevention of infection in patients with severe pancreatitis. Methods A randomized, double-blind, controlled open trial was used. Patients with clinically diagnosed severe acute pancreatitis were randomly divided into experimental group and control group, the experimental group daily application of moxifloxacin 400mg, the control group daily application of ciprofloxacin 400mg metronidazole 1.25g, the course of treatment is 7 ~ 14d, The vital signs, APACHⅡscore, blood routine, liver and kidney function, nausea, vomiting, abdominal pain and bloating were recorded in two groups. The incidence of infection and mortality were recorded. Results A total of 28 patients in both groups were enrolled in this study. Twenty-six of these patients were eligible for efficacy evaluation, and 24 patients in each group were eligible for safety evaluation. The incidence of abdominal infection was 14.3% in the experimental group and 17.9% in the control group. The incidence of adverse reactions was 15.3% in the experimental group and 20% in the control group. Conclusion In the prophylactic antibiotic treatment of acute pancreatitis, moxifloxacin alone can achieve the same effect with ciprofloxacin plus metronidazole.